Zobrazeno 1 - 10
of 123
pro vyhledávání: '"Margaret K, Yu"'
Autor:
Yuchiao Chang, Joshua R Lakin, Michael K Paasche-Orlow, Charlotta Lindvall, Areej El-Jawahri, Angelo Volandes, Aretha Delight Davis, Margaret K Yu, Nwamaka D Eneanya, Susan P Y Wong, Sushrut S Waikar, Edward T Moseley, Lori Henault, Amresh D Hanchate, Ernest I Mandel, Sophia N Zupanc, Lisa M Quintiliani, Amar D Bansal, Jane O Schell, Andrew L Lundquist, Manjula Kurella Tamura, Mark L Unruh, Christos Argyropoulos, Michael J Germain
Publikováno v:
BMJ Open, Vol 12, Iss 4 (2022)
Introduction Older patients with advanced chronic kidney disease (CKD) often are inadequately prepared to make informed decisions about treatments including dialysis and cardiopulmonary resuscitation. Further, evidence shows that patients with advanc
Externí odkaz:
https://doaj.org/article/cba2414c3fb9404da327025ffe6b1724
Autor:
Margaret K. Yu, Tara I. Chang
Publikováno v:
Clinical Journal of the American Society of Nephrology. 18:551-553
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4e0c1043bd988bbfe5398494450ddc46
https://doi.org/10.2215/cjn.0000000000000150
https://doi.org/10.2215/cjn.0000000000000150
Autor:
Fred Saad, Juhui J. Jiao, Charlene Abrams, Caly Chien, Peter Hellemans, Margaret K. Yu, Terence W. Friedlander, Gerhardt Attard, Maja J.A. de Jonge, Ronald de Wit, Kim N. Chi, Edwin M. Posadas
Duration of treatment exposure and PSA response since start of therapy for patients receiving systemic therapy with an AR signaling inhibitor prior to study entry
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af6a97e106bd3776cad7573d26bf9aa2
https://doi.org/10.1158/1078-0432.22475339.v1
https://doi.org/10.1158/1078-0432.22475339.v1
Autor:
Fred Saad, Juhui J. Jiao, Charlene Abrams, Caly Chien, Peter Hellemans, Margaret K. Yu, Terence W. Friedlander, Gerhardt Attard, Maja J.A. de Jonge, Ronald de Wit, Kim N. Chi, Edwin M. Posadas
Purpose:Apalutamide is a next-generation androgen receptor (AR) inhibitor approved for patients with nonmetastatic castration-resistant prostate cancer (CRPC) and metastatic castration-sensitive prostate cancer. We evaluated the pharmacokinetics, saf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3711af714fc0d64f3b44ad92c52c676
https://doi.org/10.1158/1078-0432.c.6529049.v1
https://doi.org/10.1158/1078-0432.c.6529049.v1
Autor:
Howard I. Scher, Margaret K. Yu, Carla J. de Boer, Edna Chow Maneval, Rajesh Bandekar, Ralph J. Hauke, Mansoor Saleh, Charles J. Ryan, Joshi J. Alumkal, Ronald F. Tutrone, Neal D. Shore, Emmanuel S. Antonarakis, Dana E. Rathkopf
Study design (A) and patient disposition (B); data cutoff December 31, 2014.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c300df8bcc216729a178ba406f6e1c63
https://doi.org/10.1158/1078-0432.22466345.v1
https://doi.org/10.1158/1078-0432.22466345.v1
Autor:
Partha Nandy, Italo Poggesi, An Vermeulen, Margaret K. Yu, Youn C. Park, Thomas W. Griffin, Fred Saad, Matthew R. Smith, Kim Stuyckens, Charles J. Ryan, Xu S. Xu
Purpose: We constructed a biomarker-survival modeling framework to explore the relationship between prostate-specific antigen (PSA) kinetics and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients following oral
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::645a97186f2009145fa6e0281b85309d
https://doi.org/10.1158/1078-0432.c.6523895
https://doi.org/10.1158/1078-0432.c.6523895
Autor:
Fred Saad, Juhui J. Jiao, Charlene Abrams, Caly Chien, Peter Hellemans, Margaret K. Yu, Terence W. Friedlander, Gerhardt Attard, Maja J.A. de Jonge, Ronald de Wit, Kim N. Chi, Edwin M. Posadas
Figure legends for Figure S1 and Figure S2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::312adf9420dc6e1c57832de0fb1cd84f
https://doi.org/10.1158/1078-0432.22475351.v1
https://doi.org/10.1158/1078-0432.22475351.v1
Autor:
Howard I. Scher, Margaret K. Yu, Carla J. de Boer, Edna Chow Maneval, Rajesh Bandekar, Ralph J. Hauke, Mansoor Saleh, Charles J. Ryan, Joshi J. Alumkal, Ronald F. Tutrone, Neal D. Shore, Emmanuel S. Antonarakis, Dana E. Rathkopf
Purpose: To evaluate the efficacy of apalutamide before or after treatment with abiraterone acetate and prednisone (AAP) in patients with progressive metastatic castration-resistant prostate cancer (mCRPC).Experimental Design: Two cohorts were studie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a57f2fb7436a220c45f1386b1764375
https://doi.org/10.1158/1078-0432.c.6526292.v1
https://doi.org/10.1158/1078-0432.c.6526292.v1
Autor:
Fred Saad, Juhui J. Jiao, Charlene Abrams, Caly Chien, Peter Hellemans, Margaret K. Yu, Terence W. Friedlander, Gerhardt Attard, Maja J.A. de Jonge, Ronald de Wit, Kim N. Chi, Edwin M. Posadas
Confirmed PSA response (as change from baseline) at any time for patients who received no prior therapy with AA-P or ENZ and patients who received therapy with AA-P only, ENZ only, or both AA-P and ENZ prior to study entry. Postbaseline PSA measureme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fe6f7f3fddf615700ffb3c7c26baf4f
https://doi.org/10.1158/1078-0432.22475345.v1
https://doi.org/10.1158/1078-0432.22475345.v1
Autor:
Partha Nandy, Italo Poggesi, An Vermeulen, Margaret K. Yu, Youn C. Park, Thomas W. Griffin, Fred Saad, Matthew R. Smith, Kim Stuyckens, Charles J. Ryan, Xu S. Xu
Supplemental Methods, Table 1 and Figures 1-2. Appendix I: TGI PSA kinetic model, Appendix II: Survival analysis. Supplementary Table 1. Parameter estimates of the final PSA kinetic model. Supplementary Figure 1. Diagnostic plot of the observed and p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a1f9610f7e3778e0a06a2142f3b292c
https://doi.org/10.1158/1078-0432.22458281
https://doi.org/10.1158/1078-0432.22458281